INTRODUCTION
Enhancing factor (EF), a secretory phospholipase A # (sPLA # ), was first isolated in our laboratory from mouse intestines as a growth-factor modulator. EF increases the binding of epidermal growth factor (EGF) to A431 cells in the radio-receptor assay [1] [2] [3] . It was proposed that EF binds to a 100 kDa receptor on the cell surface, traps EGF and makes it available to the cell, thereby giving it a growth advantage [2] . Immunohistochemical studies have demonstrated that EF is localized predominantly in the Paneth cells of small intestine [4] [5] [6] and has been used as a marker for Paneth cells [7] . Sequence analysis [8, 9] and phylogenetic analysis have shown that EF belongs to the class of membrane-associated PLA # s [10] . PLA # s have been isolated from various sources and studied extensively, although their function has yet to be determined fully. X-ray analyses from several PLA # s show that the enzymes are structurally similar. The low-molecular-mass (14 kDa) PLA # s are characterized by a rigid three-dimensional structure held together by disulphide bridges and require Ca# + for their catalytic activity [11] . PLA # s have also been shown to bind heparin, and the catalytic activity of porcine pancreatic PLA # has been shown to be inhibited by heparin [12] . However, Murakami et al. [13] have reported that neither mouse nor rat sPLA # activities were inhibited by heparin in their assay system. We have reported that heparin inhibits enhancing activity as well as PLA # activities [14] . The increased binding of EGF to the cells by EF could be explained in two ways. EF, by its inherent ability to hydrolyse phospholipids, could expose cryptic EGF receptors on the cell surface, or EF could bind to its own cell-surface receptor and in Abbreviations used : EF, enhancing factor ; PLA 2 , phospholipase A 2 ; sPLA 2 , secretory PLA 2 ; EGF, epidermal growth factor ; RACE, rapid amplification of cDNA ends ; RT, reverse transcriptase ; UTR, untranslated region ; DMEM, Dulbecco 's modified Eagle 's medium ; rEF, recombinant EF. 1 To whom correspondence should be addressed (e-mail cri3!soochak.ncst.ernet.in).
are independent of each other, a series of mutations were created using the full-length EF cDNA as a template, expressed in 293 cells and the mutant recombinant proteins checked for EF as well as PLA # activities. Our studies have shown that one of the mutant EF proteins, lacking PLA # activity, retains EF activity. This demonstrates unambiguously that EF and PLA # activities are two independent activities in the same molecule. Mutation in the Ca# + -binding loop resulted in loss of EF activity, thereby demonstrating that EF activity is Ca# + -dependent. The Nterminal region of the EF molecule appears to be crucial for the enhancing activity.
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turn offer a binding site for EGF. Whereas EF protein has been found to have PLA # activity [8] , it was not evident whether the enhancing activity is dependent on the PLA # activity. Since the structures of PLA # molecules have been well established and the different active sites defined, it was proposed to mutate the enzyme active site(s) and examine the activities of the mutated molecules. In the present study we report cloning and expression of wild-type and mutant EF cDNAs expressed in 293 cells and functional characterization of the recombinant protein.
MATERIALS AND METHODS

Amplification and cloning of wild-type and mutant EF cDNAs
The full-length EF cDNA was obtained by rapid amplification of cDNA ends (RACE)-reverse transcriptase (RT)-PCR and cloned into pUC vector as described by Kadam et al. [10] . The 733 bp full-length EF cDNA insert from pUC was excised with HindIII\ XbaI and religated to the mammalian expression vector, pRc\ CMV (InVitrogen), cut with the same enzymes. During RACE-RT-PCR, one of the full-length cDNA products amplified using primers P5 and P6 (Table 1) , encompassing 87 bp of the 5h-untranslated region (UTR), 441 bp of the complete open reading frame and 264 bp of the 3h-UTR (total 792 bp), was found to have a point mutation at the nucleotide position 149 after the first ATG codon, which resulted in substitution of A in place of G. This mutant cDNA was designated SK-8m.
Mutant EF cDNAs were obtained by nested PCR strategy, using wild-type full-length EF cDNA as a template and combinations of EF-specific nested primers (as shown in Table 1 ). For one of the mutants, SK-3.5m, point mutations were intro- duced in the antisense primer [primer EF(FC3), Table 1 ] such that Lys""* and Lys"#" were mutated to Glu""* and Glu"#". PCR amplifications were carried out using Taq DNA polymerase (Amersham) for 30 cycles at 95 mC for 1 min, 55 mC for 2 min and 72 mC for 3 min. After the last cycle, extension was carried out at 72 mC for 10 min. After confirming the size of the amplified products on an ethidium bromide-stained agarose gel, they were cloned into a pUC vector for sequencing using the Sure Clone ligation kit (Pharmacia), and sequenced using Sequenase version 2 (USB Amersham). After confirming the nucleotide sequences, the inserts were excised using HindIII\XbaI and ligated into pRc\CMV cut with the same enzymes. Plasmid DNA was prepared on a large scale from positive clones by standard procedures and purified on columns (Qiagen). After quantification, the DNA was used for transfections.
Transfection of HEK-293 cells with cDNAs for wild-type and mutant EF genes
HEK-293 cells (1i10&) were seeded in 60 cm tissue culture plates (Nunc) in Dulbecco 's modified Eagle 's medium (DMEM) containing 10 % bovine calf serum (Hyclone). The cells were transfected with lipofectin (Gibco-BRL) using standard procedures. Briefly, 2 µg of each construct DNA was mixed with 10 µl of lipofectin in 200 µl of DMEM and allowed to stand at room temperature for 15 min. The cells were washed twice in DMEM and incubated with 1.8 ml of DMEM. The DNAlipofectin complex was then added dropwise to the cells and incubated for 6 h at 37 mC in a 5% CO # incubator. After 48 h the transfectants were selected on G-418 (800 µg\ml). The antibioticresistant clones were screened for the recombinant protein by immunostaining using antibodies to EF (results not shown). One representative clone, positive by immunostaining, from each of the individual transfection reactions was characterized further. The designations of the different transfectants and their properties are shown in Table 2 .
Extraction and purification of acid-soluble proteins from HEK-293 transfected cells
Acid-soluble proteins were extracted from wild-type and transfected 293 cells using protocols standardized in our laboratory for extraction of EF from mouse intestines [1] . Cells from 10 subconfluent 100 mm Petri plates (Nunc) were washed thrice with PBS and harvested for extraction. Recombinant EF protein (rEF) was purified from total acid-soluble proteins on a heparinaffinity HPLC column (TSK, Tosoh), as described by Wagle et al. [14] . Briefly, 2 mg of total acid-soluble protein was dissolved in 500 µl of 0.02 M phosphate buffer, pH 7.5, and injected on to the column pre-equilibrated with the same buffer. The proteins were eluted using a gradient of 0-2 M NaCl in phosphate buffer, at a flow rate of 1 ml\min. EF was shown to elute at 0.8 M NaCl from earlier studies [14] . Hence, peaks in that range were collected individually, lyophilized and tested.
Immunoblotting
Acid-soluble proteins from transfected 293 and wild-type cells were separated on SDS\PAGE (17.5 % gel) and transferred to nitrocellulose membrane (Hybond-N, Amersham). Blocking was carried out overnight using 3 % BSA in Tris-buffered saline at room temperature. The blot was incubated with rabbit polyclonal anti-EF antiserum (1 : 10 000) as described by Mulherkar et al. [5] . For visualization of the protein bands, an enhanced chemiluminescence (ECL) Western-blot analysis kit (Amersham) was used according to the manufacturer 's instructions.
Measurement of enhancing activity
Enhancing activity was measured as described earlier [1] using A431 cells and "#&I-EGF. Lyophilized test protein was dissolved in 100 µl of binding buffer and added to the cells with 100 µl pf "#&I-EGF (counts adjusted to 30 000 c.p.m.\100 µl, specific activity $ 80 µCi\µg). Non-specific binding was determined in the presence of 50 ng of unlabelled EGF. Cells were lysed in lysis buffer and counted in a gamma counter. The enhancing activity was calculated as the percentage of EGF bound above the control level. Non-specific binding was subtracted from all the readings. Each assay was carried out at least thrice, in duplicate.
PLA 2 assay using labelled Escherichia coli membranes
PLA # assay was carried out using labelled autoclaved E. coli as described by Elsbach and Weiss [15] . Briefly, 1 ml of overnight XL1-cell culture was diluted with 75 ml of Luria-Bertani medium containing 175 µl of [$H]oleic acid (10 Ci\mmol ; NEN Life Sciences Products) and incubated further for 8 h After washing the labelled cells with 50 ml of Luria-Bertani medium followed by 50 ml of Tris\BSA [1 % BSA (Sigma) in 100 mM Tris (pH 8)] the cells were resuspended in 2 ml of 140 mM NaCl\20 mM Tris (pH 8)\2 % BSA. Aliquots (100 µl) of the labelled cells were stored frozen. Incorporation of the label was $ 40 %. For the assay, labelled E. coli cells were washed and resuspended in PLA # buffer [100 mM Tris (pH 8)\10 mM CaCl # \0.1 % BSA] such that 100 µl had $ 100 000 c.p.m. Labelled membranes (100 µl ; substrate) were added to serial dilutions of the acid\ethanol-extracted test samples. Biogel P100 purified mouse intestinal EF served as the positive control and wild-type 293 cells as the negative control. The reaction was carried out at room temperature for 1 h after which 250 µl of chilled stop buffer (100 mM EDTA in 1 % BSA) was added. Supernatant (400 µl) was collected for counting in the beta counter. The data were plotted as c.p.m. released against concentration of the protein.
Heparin binding and Western-blot analysis
Approx. 10 µg aliquots of HPLC-purified intestinal EF and rEF, and 100 µg of crude acid-soluble 293\SK-3.5m protein, were each mixed with 100 µl of heparin-Sepharose beads (Pharmacia), prewashed and suspended in 500 µl of phosphate buffer and incubated overnight at 4 mC. After incubation, the suspension was centrifuged and the supernatant saved as the unbound protein fraction for Western blotting. The beads were washed three times with phosphate buffer. The heparin-bound proteins were eluted using 2 M NaCl in phosphate buffer, dialysed against Enhancing activity is independent of phospholipase A 2 activity MilliQ water, lyophilized and subjected to immunoblotting, along with the unbound fraction, as described earlier.
RESULTS
Cloning and expression of wild-type full-length EF cDNA in 293 cells
The 
Characterization of rEF
Earlier studies in our laboratory have shown that EF is a heparin-binding protein [14] . Hence, rEF protein was purified from the crude acid-soluble proteins using a heparin-affinity column. The HPLC profiles of acid-soluble proteins extracted from intestines and 293\SK-15 cells were similar (Figure 2 ). Each peak was collected individually and tested for enhancing activity. The activity was found to be present in the peak eluting at approx. 18 min in both intestinal proteins as well as 293\SK-15 proteins, but not in non-transfected 293 cells (Table 3) . Heparinaffinity-purified rEF showed more than 100 % enhancing activity, which could be abrogated in the presence of heparin (Figure 3) . PLA # activity could also be abolished by heparin in the blood 
Figure 3 Enhancing activity of heparin-affinity-purified rEF protein in the presence or absence of heparin
Radio-receptor assay was carried out in duplicate wells using different concentrations of purified rEF in the presence (j) or absence (k) of 10 units of heparin.
125 I-EGF binding in the absence of any additives was considered as a baseline (control). The data from one representative experiment are given as meanspS.E.M. agar assay (results not shown). Approx. 1.7 mg of purified EF protein was obtained from 7.8i10( 293\SK-15 cells.
Point mutation in the Ca 2 + -binding loop
During amplification of the full-length EF cDNA, one of the $ 800 bp EF cDNAs was found to contain a point mutation at nucleotide position 149 after the first ATG, which resulted in substitution of an A in place of a G, a change from Gly#* (GGC) to Asp#* (GAC) of the mature EF protein (corresponding to position 30 in the aligned PLA # sequences). This mutation was found to be in the highly conserved Gly$! residue of the PLA # molecule, which is involved in the Ca# + -binding domain [16] . The mutant EF cDNA was cloned into the expression vector pRc\ CMV. One of the G-418-resistant clones, designated 293\SK-8m, was selected by immunostaining (results not shown) and cultured for protein extraction.
Figure 4 Enhancing activity of wild-type and mutant rEF proteins
Radio-receptor assay was carried out in duplicate wells as described in the Materials and methods section. Control wells had no protein added to A431 cells. Intestinal EF, purified on HPLC (HPLC-IEF) served as a positive control. Proteins extracted from wild-type 293 cells served as negative control. The experiment was carried out more than three times and data from one representative experiment are given as meanspS.E.M.
Deletion mutants and point mutations in the C-terminal cationic residues
Deletion mutants of EF cDNAs were obtained by nested PCR strategy, subcloned in pRc\CMV and transfected into 293 cells. 293\SK-60m carried a deletion in the C-terminal end, ∆83-125, (Table 2 ) and 293\SK-14m carried a deletion in the N-terminal region, ∆1-37. 293\SK-3.5m carried point mutations in the putative C-terminal heparin-binding residues, Lys""* Glu and Lys"#" Glu (Table 2) . Acid-soluble proteins from all the transfected cell lines were extracted and tested for enhancing activity and PLA # activity. 293\SK-60m and 293\SK-3.5m showed enhancing activity comparable with 293\SK-15 as well as intestinal EF protein (Figure 4 ). 293\SK-8m and 293\SK-14m did not show any enhancing activity (Figure 4 ). Considerable PLA # activity was Enhancing activity is independent of phospholipase A 2 activity seen in EF P100, 293\SK-15 and 293\SK-3.5m, whereas 293\SK-60m did not show any PLA # activity ( Figure 5 ). 293\SK-14m as well as 293\SK-8m were devoid of PLA # activity ( Figure 5 ). 293\SK-3.5m exhibited PLA # activity comparable with 293\SK-15. A summary of the wild-type and mutant EF protein structures and activities is shown in Figure 6 .
Figure 6 Wild-type and mutant EF protein structures and their properties
The structures of the proteins used in the study and their enhancing and PLA 2 activities are shown. SP, signal peptide. The numbers in the line diagram denote the amino acid residues in the mature EF protein.
Figure 7 Heparin-binding property of SK-3.5m
Acid-soluble proteins from intestinal EF (HPLC-IEF, lanes 1 and 2) , 293/SK-15 (lanes 3 and 4) and 293/SK-3.5m (lanes 6 and 7) were incubated with heparin-Sepharose beads as described in the Materials and methods section. The unbound (lanes 1, 3 and 6 ) and eluted proteins (lanes 2, 4 and 7) were separated by SDS/PAGE (17.5 % gel). Samples were analysed by immunoblotting using rabbit polyclonal anti-EF antiserum at 1 : 10 000 dilution and visualized using an ECL kit (Amersham).
Heparin-binding property of mutant rEF
To check whether the C-terminal cationic residues were involved in heparin binding, acid-soluble proteins from 293\SK-3.5m cells were incubated with heparin-Sepharose beads. On Western-blot analysis of the bound proteins, a 14 kDa band was observed in the extract from 293\SK-3.5m ( Figure 7 Figure  7, lane 3) . Although a faint 14 kDa band was seen in the unbound fraction in 293\SK-3.5m ( Figure 7 , lane 6) the majority of the protein was found to be bound to the heparin-Sepharose beads ( Figure 7, lane 7) . Mutation in the C-terminal cationic residues Lys""* and Lys"#" did not appear to interfere with the heparin-binding property of EF.
DISCUSSION
EF is a 14 kDa molecule isolated from mouse small intestines, identified by its ability to increase the binding of "#&I-EGF to A431 cells in the radio-receptor assay [1, 2] . In the presence of EGF, EF stimulates DNA synthesis in itro in NR6 cells (cells devoid of functional EGF receptors) as well as inducing anchorage-independent growth in normal rat fibroblasts [2] . Therefore, we have proposed that EF gives the cell a growth advantage by making EGF available to it. To explain the increased binding, we had proposed that EF binds to its own cellsurface receptor and in turn offers a binding site for EGF [2] .
On sequencing the EF protein as well as the cDNA, EF was found to be a sPLA # , belonging to group II [8, 9] . Hence there was a possibility that the enhancing activity was brought about by hydrolysing phospholipids on the cell surface and exposing cryptic EGF receptors, thereby increasing the EGF binding. Besides having structural similarity to rat and human sPLA # , EF also shared some functional characteristics with PLA # . EF was found to require Ca# + for its enhancing activity (S. Kadam and R. Mulherkar, unpublished observations) and the enhancing activity could be blocked with heparin [14] . Whether enhancing activity was dependent on phospholipase activity or not had to be investigated. Modifying the PLA # active sites in the EF molecule would help in understanding whether the enzyme action is essential for enhancing activity or whether the two activities are independent of each other.
rEF is secreted but is tightly bound to the membrane
The full-length EF cDNA, 293\SK-15, expressed in 293 cells, was found to be identical to the native, intestinal EF. Although rEF was secreted out, it was found to be tightly associated with the membranes and could be dissociated with 1 M NaCl (results not shown). Phylogenetic analysis of the mammalian PLA # family using 16 aligned PLA # sequences has shown previously that mouse EF belongs to the membrane-associated PLA # family with a bootstrap value of 98 % [10] . There have been reports that the membrane-associated PLA # s are essentially identical to sPLA # but, unlike sPLA # , tightly associated with the membrane [17] . Ishizaki et al. [18] have reported that PLA # from rat spleen is tightly associated with the membrane and that sorting machinery within the cell plays a crucial role in anchoring the molecule to the cell surface, whereas Ono et al. [17] have reported that the association of the PLA # from rat spleen with the membrane fraction could be due to the cluster of hydrophobic amino acid residues on the molecular surface.
EF does not bind heparin via C-terminal cationic residues
PLA # s have been shown to bind to heparin-like cell-surface molecules [19] [20] [21] [22] [23] . EF also binds heparin, and heparin inhibits EF activity by blocking its binding site on the cell membrane [14] . Cationic residues involved in heparin binding are highly conserved in the rat, human and mouse PLA # sequences. Murakami et al. [13] demonstrated by site-directed mutagenesis that the Cterminal residues Lys""* and Lys"#" are important for association of the mouse sPLA # with heparin and cell surfaces, although they are not essential for the catalytic activity. Their results showed that mutations in the two residues resulted in a reduced capacity of the molecule to bind to heparin and cell-surface heparan sulphate proteoglycans compared with wild-type sPLA # [13] . In our studies, mutant 293\SK-3.5m, carrying similar mutations in the C-terminal Lys residues (Lys""* Glu and Lys"#" Glu), could bind heparin (although the affinity for heparin was not checked), and demonstrated both enhancing and PLA # activities. This suggests that the ability of the mutant EF to bind to the cell surface and bring about an increase in the binding of EGF was not affected. Diccianni et al. [23] have shown that a peptide corresponding to 26 residues at the N-terminal end of porcine pancreatic PLA # can rescue PLA # from heparin inhibition. Dua and Cho [24] have also reported that the cationic residues at the N-terminal region of the human sPLA # are responsible for interaction with the heparin. Based on the present data and our earlier studies [14] , we propose that the N-terminal basic residues, Arg"!, Lys"#, Lys"& and Arg"', could be involved in heparin binding.
Enhancing activity is Ca
2 + -dependent sPLA # s have been shown to be dependent on Ca# + for their enzymic activity [25] . All catalytically active sPLA # s are known to have a Ca# + -binding loop with a highly conserved consensus motif, Xaa-Cys-Gly-Xaa-Gly [26] . Gly$! and Asp%* have been found to be essential for the enzymic activity and are highly conserved in all sPLA # s [16, 25, [27] [28] [29] . This motif is present in the EF molecule as well [9] . A full-length EF cDNA obtained by PCR strategy had a point mutation at the nucleotide position 149 from the ATG, resulting in an amino acid change from Gly to Asp at position 29 (position 30 when aligned with other sPLA # s). This point mutation was found to be in the Ca# + -binding loop. In studies from our laboratory, EF activity was found to be lost if Ca# + was depleted from the binding medium, thus indicating that enhancing activity is Ca# + -dependent (results not shown). The mutant protein confirmed this observation. Recombinant protein from 293\SK-8m showed neither enhancing activity nor PLA # activity. It is possible that the Ca# + ion stabilizes the EF molecule and plays an important role in EGF binding. SK\293-60m has the Ca# + -binding loop and displays enhancing activity, whereas in SK\293-14m this region is deleted and the molecule is devoid of enhancing activity.
Enhancing activity in deletion mutants
Sites and patterns detection analysis [30] , and comparison of the EF sequence with known PLA # molecules, suggested the existence of two PLA # active sites centred on His%) and Asp""$ [31] . A deletion mutant, 293\SK-60m, which had a 43 amino acid deletion at the C-terminal end, retained its enhancing activity but showed no PLA # activity. This demonstrates that enhancing activity is independent of PLA # activity. Another mutant, 293\SK-14m, which had an N-terminal deletion of 37 amino acid and an intact C-terminal end, with a molecular mass of 10 kDa, shows no enhancing activity and no PLA # activity. This was expected, as the Ca# + -binding loop was deleted from the molecule. The ability of the molecule to bind the cell surface as well as EGF appears to reside in the N-terminal end.
Mechanism of action of EF
To explain the mechanism of action of enhancing activity based on the present data, we once again propose that EF binds to the cell surface, presumably via heparan sulphate proteoglycans, and in turn offers a binding site for EGF. EF by itself may not be able to bind EGF but when bound to its cell-surface receptor could be creating a binding site for EGF. The mutation-analysis studies indicate that the enhancing activity and the phospholipase activity are independent of each other and that the N-terminal end of the EF molecule is perhaps involved in the enhancing activity. Whether the EF-EGF complex is responsible for transducing signals into the cell or whether it only sequesters EGF molecules on the cell surface is not yet clear.
EF appears to be a molecule with dual function ; growth modulation via increased EGF binding, and phospholipase A # activity. There are other reports of such bifunctional molecules. Tissue inhibitor of metalloproteinase is a molecule that has both anti-protease activity and growth-factor activity [32] . PLA # from bovine seminal plasma has been shown to be a platelet-activating factor acetylhydrolase [33] . Rosenberg et al. [34] have reported that in the neurotoxic snake venom PLA # , the N-terminal region and basic residues away from the enzymic active-site region are important in neurotoxicity and may occur independently of phospholipid hydrolysis. Based on our studies, we propose that the N-terminal region of the EF molecule is important in the EGF-binding activity and that one of the functions of the mammalian sPLA # molecules could be growth modulation.
